Pangen Biotech Inc
222110
Company Profile
Business description
Pangen Biotech Inc is a biotechnology company. The company is engaged in the production and sales of biosimilar EPO drugs, contract manufacturing (CMO), and development technology transfer service (CDO) business for biopharmaceuticals, including non-clinical and clinical samples, and biopharmaceutical development business.
Contact
306 Sinwon-ro, Yeongtong-gu
4th floor, Yeongtong Innoplex 2nd building, Woncheon-dong
Gyeonggi-do
Suwon-si
KORT: +82 317339165
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
75
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
stocks
ASX listed media giant drives strong earnings growth
Digital growth drives earnings beat for media share.
stocks
ASX real estate platform outperforms yet questions remain
Valuation remains a key concern despite strong August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,412.60 | 24.80 | -0.26% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,881.84 | 213.81 | 0.83% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,931.48 | 1,324.77 | 2.02% |
| NZX 50 Index | 13,845.70 | 21.57 | 0.16% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,220.80 | 28.80 | -0.31% |
| SSE Composite Index | 3,948.64 | 8.60 | 0.22% |